ROBOTIC COMPOUNDING: SAFETY AND PRODUCTIVITY ACHIEVEMENTS IN THE PREPARATION



OF HAZARDOUS DRUGS

López-Cabezas C, Marín AM, Riu G, Codina C, Soy D. Pharmacy Department. Hospital Clinic Barcelona mclopez1@clinic.cat



OBJECTIVE:

Evaluate the impact on **safety** and **productivity** after the implementation of Kiro® Oncology automated device.









METHODS:

FMECA:

Failure Mode, Effect and Criticality Analysis to identify risks related to the manual and robotic compounding processes (1-4 scale for Criticality Index (CI), based on severity, ocurrence and detection capacity)

Patient safety:

Percentage of preparations within the ±5% accuracy range evaluated by gravimetric control in a sample for 9 common drugs prepared manually and using the robotic system

User safety:

Number of high-volume (>20mL) preparations using 50mL syringes from March to August 2018

Productivity:

Evolution of production in the robot from May 2017 to August 2018, expressed as mean, minimum and maximum number of preparations per day

CONCLUSIONS:

i) Robotic compounding is expected to decrease the global risk of failures in the compounding process due to less human intervention in some critical tasks, and to avoid repeated stress injuries related to the use of high-volume syringes. ii) The use of robotic compounding in our setting showed similar accuracy rates to manual compounding. iii) The amount of preparations completed by the robot has gradually increased, and strategies based on technical improvements and optimization of cycle management will be implemented in order to achieve our productivity goals.



Failure modes grouped by categories and Cl



99.8% 96.9% 1.11 (0.29) No significant differences observed



3372 high volume syringes handling avoided in 6 months



At the end of the study period: 50 prep/day (max 90); 40% total production

24th EAHP Congress Barcelona, 27-29 March 2019

